Clearside Biomedical

CLSD · NASDAQ

Price unavailable right now.

No price history for this range.

CLSD analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 4 analysts

Average $84.15

Low: $75.75
High: $94.50

Upgrades and downgrades

The latest rating actions, newest first

CLSD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Hit rate
Needham	Nov 18, 2025	Maintains	Hold	53%

The case for and against

Updated Nov 28, 2025

Bull case

Clearside Biomedical Inc. has garnered increasing interest from the retina community for its suprachoroidal therapeutics, signaling a positive industry reception. The company successfully gained approval for its suprachoroidal product, Xipere, which is currently available in the U.S., enhancing its market position. Additionally, promising results from the Phase 2b ODYSSEY trial for the CLS-AX program indicate potential for further advancements in the treatment of wet age-related macular degeneration and highlight the strategic value of future partnerships to leverage its innovative SCS Microinjector technology.

Bear case

Clearside Biomedical faces significant risks regarding the efficacy and safety of its retinal disease treatment candidates, which may impede the company's ability to secure regulatory approvals. The company has struggled to find a strategic partner for its CLS-AX program, indicating potential diminished interest in its suprachoroidal delivery system compared to alternative treatment methods. Furthermore, uncertainties surrounding key patents could lead to inadequate asset protection, adversely impacting Clearside's market viability and prompting downward revisions to its valuation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.